HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn's disease patients.
暂无分享,去创建一个
A. Masamune | Y. Kakuta | Y. Kawai | Y. Kinouchi | R. Moroi | H. Shiga | T. Naito | M. Nagasaki | Yusuke Shimoyama | K. Tokunaga | Fumiko Shimoda | Rintaro Moroi | Takeo Naito
[1] J. Ludvigsson,et al. Predictors of drug survival: A cohort study comparing anti‐tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register , 2021, Alimentary pharmacology & therapeutics.
[2] A. Berghold,et al. Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study , 2021, Alimentary pharmacology & therapeutics.
[3] B. Boyle,et al. Real‐World Infliximab Pharmacokinetic Study Informs an Electronic Health Record‐Embedded Dashboard to Guide Precision Dosing in Children with Crohn’s Disease , 2020, Clinical pharmacology and therapeutics.
[4] Xiao-Jun Liang,et al. LncRNA SNHG7 alleviates IL-1β-induced osteoarthritis by inhibiting miR-214-5p-mediated PPARGC1B signaling pathways. , 2020, International immunopharmacology.
[5] S. Brand,et al. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User’s Guide: An Update , 2020, Digestion.
[6] R. Kim,et al. HLADQA1*05 genotype predicts anti‐drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease , 2020, Alimentary pharmacology & therapeutics.
[7] J. Cidlowski,et al. Inhibition of miR-378a-3p by Inflammation Enhances IL-33 Levels: A Novel Mechanism of Alarmin Modulation in Ulcerative Colitis , 2019, Front. Immunol..
[8] J. Barrett,et al. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. , 2019, Gastroenterology.
[9] P. Rutgeerts,et al. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[10] W. Sandborn,et al. Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience , 2018, Inflammatory bowel diseases.
[11] Hui Shen,et al. PPARGC1B gene is associated with Kashin-Beck disease in Han Chinese , 2016, Functional & Integrative Genomics.
[12] S. Bae,et al. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis , 2016, Rheumatology International.
[13] H. Hakonarson,et al. Molecular Sciences Association between Genetic Polymorphisms and Response to Anti-tnfs in Patients with Inflammatory Bowel Disease , 2022 .
[14] S. Vermeire,et al. Review article: pharmacological aspects of anti‐TNF biosimilars in inflammatory bowel diseases , 2015, Alimentary pharmacology & therapeutics.
[15] J. Yasuda,et al. Japonica array: improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals , 2015, Journal of Human Genetics.
[16] B. Weiss,et al. Infliximab-Related Infusion Reactions: Systematic Review , 2015, Journal of Crohn's & colitis.
[17] Joris M. Mooij,et al. MAGMA: Generalized Gene-Set Analysis of GWAS Data , 2015, PLoS Comput. Biol..
[18] Carson C Chow,et al. Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.
[19] A. Moschetta,et al. PGC-1β promotes enterocyte lifespan and tumorigenesis in the intestine , 2014, Proceedings of the National Academy of Sciences.
[20] Jianjun Liu,et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia , 2014, Nature Genetics.
[21] Jing Wang,et al. CrossMap: a versatile tool for coordinate conversion between genome assemblies , 2014, Bioinform..
[22] M. Blennerhassett,et al. Inflammatory cytokines promote growth of intestinal smooth muscle cells by induced expression of PDGF-Rβ , 2014, Journal of Cellular and Molecular Medicine.
[23] P. V. Schouwenburg,et al. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis , 2013, Nature Reviews Rheumatology.
[24] D. Mould,et al. Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.
[25] Honghui Zhou,et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. , 2011, Clinical therapeutics.
[26] S. Ben-Horin,et al. Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.
[27] F. Magro,et al. Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies , 2010, BioDrugs.
[28] Michael Boehnke,et al. LocusZoom: regional visualization of genome-wide association scan results , 2010, Bioinform..
[29] M. Krzystek-Korpacka,et al. Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease. , 2009, Clinical biochemistry.
[30] P. Tak,et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.
[31] D. Greaves,et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. , 2006, Cell metabolism.
[32] T. Shimosegawa,et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity , 2013, Immunogenetics.